Interaction of Avilamycin with Ribosomes and Resistance Caused by Mutations in 23S rRNA
AUTOR(ES)
Kofoed, Christine B.
FONTE
American Society for Microbiology
RESUMO
The antibiotic growth promoter avilamycin inhibits protein synthesis by binding to bacterial ribosomes. Here the binding site is further characterized on Escherichia coli ribosomes. The drug interacts with domain V of 23S rRNA, giving a chemical footprint at nucleotides A2482 and A2534. Selection of avilamycin-resistant Halobacterium halobium cells revealed mutations in helix 89 of 23S rRNA. Furthermore, mutations in helices 89 and 91, which have previously been shown to confer resistance to evernimicin, give cross-resistance to avilamycin. These data place the binding site of avilamycin on 23S rRNA close to the elbow of A-site tRNA. It is inferred that avilamycin interacts with the ribosomes at the ribosomal A-site interfering with initiation factor IF2 and tRNA binding in a manner similar to evernimicin.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=128742Documentos Relacionados
- Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations.
- Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori.
- Mutations in a 23S rRNA Gene of Chlamydia trachomatis Associated with Resistance to Macrolides
- Macrolide Resistance Conferred by Base Substitutions in 23S rRNA
- Chloramphenicol-erythromycin resistance mutations in a 23S rRNA gene of Escherichia coli.
